Products

TalkChar

Dare to talk, connect, grow with character of your choice

talkchar.com Entertainment & Media / AI Companions & Character Chat

AI Benchmark
Monthly visits
<5K
Oct 2026
Public revenue
Undisclosed
No public revenue evidence yet
Entry price
Unknown
No monthly subscription pricing
Creators
Unlinked
No verified creators
Launched
3y ago
2023-08-04 · Est.

Traffic

Monthly visitsData through Oct 2026

Marketing moves

Launches, search & content, referrals, promotions
  • Launched on V2EX (5 comments)Launch

    🎭 TalkChar. 又一个虚拟角色对话产品 - 发了 ProductHunt,顺便求个 upvote — 1️⃣ TalkChar 是什么? TalkChar 是一个 AI 虚拟角色对话平台,让您与您喜爱的角色进行对话。无论您热衷于视频游戏🎮、哲学📚、心理学🧠还是音乐🎵,我们都为每个人提供了一些内容。 2️⃣ 我们想听听你的声音!📣 您最期待与哪些角色交谈? 您希望我们…

    Aug 4, 2023 · 3y agoLaunch page

  • Launched on Product HuntLaunch

    Dare to talk, connect, grow with character of your choice

    Aug 4, 2023 · 3y agoLaunch page

Traffic sources

Oct 2026

Traffic breakdown

Channels

No data yet

Countries

No data yet

Search

Domain authority —Domain registered 2025-10-06

No search keyword data for this website yet.

Traffic data: Vaneform

Pricing

Pricing page not identified yet, or no public pricing listed.

Pages & changes

Tracked since 2023-08-04

Key pages

Weekly snapshots

No page snapshots yet. Once followed, home and pricing pages are captured weekly.

Changes

No pricing, plan, or positioning changes detected since tracking started.

Questions & evidence

How much website traffic does TalkChar get?
Vaneform estimates <5K website visits in 2026-10. Visits can include repeat visits; this estimate measures web traffic separately from paying customers or revenue.Source
What is TalkChar and what platforms does it support?
TalkChar is catalogued under AI Companions & Character Chat: Dare to talk, connect, grow with character of your choice. Supported platforms: Web.

Related products in this category

Entertainment & Media / AI Companions & Character Chat

These products share a catalog category. Compare customer tasks, features and deployment requirements before treating them as alternatives.